Physician

Brian Colwell Jensen, M.D.

According to 2025 Medicare claims, Brian Jensen, M.D. (NPI: 1639231392) practices advanced heart failure and transplant cardiology in the Raleigh-Cary, NC market, with the plurality of this provider's patient population coming from Wake, NC. This provider's primary affiliated billing organization is UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (NPI: 1780669200; TIN: 561732213) and primary practice location at 27514-4220. Jensen is affiliated with the CHESS Genesis, LLC (ACO ID: D0237), participating under the REACH model.

Jensen's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 96 traditional Medicare patients, billed 255 HCPCS/CPT codes, and received $22,978 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 1,048 prescription claims across 133 beneficiaries totaling $511,337 in drug costs, led by Entresto (Sacubitril/Valsartan). DME data shows 110 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $50,653 to $22,978. In contrast, Part D prescription costs have moved sharply higher in recent years, from $24,064 to $511,337. For DME billing, this smaller-volume category started with an early spike, then settled into a lower baseline, moving from $10,858 to $431.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	165	751	$50,653
2016	338	863	$51,749
2017	170	634	$41,543
2018	159	475	$30,053
2019	137	486	$32,214
2020	151	511	$35,247
2021	148	510	$40,480
2022	126	400	$30,377
2023	104	331	$29,793
2024	96	255	$22,978

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	60	442	$24,064
2016	89	716	$39,856
2017	107	796	$110,949
2018	99	739	$95,162
2019	112	749	$308,802
2020	120	876	$489,427
2021	134	1,048	$460,309
2022	153	1,242	$808,178
2023	152	1,187	$727,975
2024	133	1,048	$511,337

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	135	$62,346
2016	N/R	N/R	N/R
2017	N/R	59	$6,306
2018	N/R	112	$9,631
2019	N/R	27	$599
2020	N/R	114	$13,691
2021	N/R	187	$19,330
2022	N/R	253	$21,414
2023	N/R	140	$11,674
2024	N/R	110	$1,807

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	14	14	$129
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	14	19	$99
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	26	115	$88
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	34	41	$67

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Entresto	Sacubitril/Valsartan	96	4,833	$102,990
Jardiance	Empagliflozin	39	3,000	$58,882
Eliquis	Apixaban	38	1,920	$36,164
Praluent Pen	Alirocumab	16	672	$11,317
Vascepa	Icosapent Ethyl	12	360	$4,003

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	26	$676
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	31	$565
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	29	$339
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	24	$227

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Brian Colwell Jensen, M.D.?

Tedicare shows public-source Medicare data for Brian Colwell Jensen, M.D. (NPI 1639231392), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Brian Colwell Jensen, M.D. have ACO affiliation data?

Brian Colwell Jensen, M.D. is shown with ACO affiliation data for CHESS Genesis, LLC (REACH, ACO ID D0237).

What billing organization is linked to Brian Colwell Jensen, M.D.?

Brian Colwell Jensen, M.D. is linked to UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (billing NPI 1780669200) in the available physician profile data.

Does Brian Colwell Jensen, M.D. have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.